By the numbers for 2018: The top 100 venture players in biotech — and who's been paying the piper in cancer R&D?
The explosion of oncology R&D over the past few years has had a dramatic impact on a variety of fronts, all clearly illustrated in these lineups of the top 100 venture investors in biotech from Chris Dokomajilar at DealForma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
